All In Biotech

Investigational drug · Phase 3

GEM

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

4 still active

All registered trials

214

Any phase or sponsor naming "GEM"

First trial start

2022

Oct 17, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "GEM", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Pancreatic Cancer
  • Recurrent or Metastatic Cervical Cancer
  • Pancreatic Cancer Metastatic
  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Pancreatic Adenocarcinoma Metastatic
  • Pancreatic Adenocarcinoma
  • Pancreatic Adenosquamous Carcinoma
  • Advanced Pancreatic Carcinoma

Approved drugs for the same conditions: Pancreatic cancer · Cervical cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "GEM" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8,501 on PubMed

Also in development for Pancreatic Ductal Adenocarcinoma (PDAC)

  • SerplulimabHLX10, HLX43Phase 325 trials

    Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • zoldonrasibPhase 34 trials

    Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC

  • [18F]FAPI-74 PETPhase 33 trials

    SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction

  • Precemtabart tocentecanPrecem-TcT, M9140Phase 32 trials

    EMD Serono Research & Development Institute, Inc. · Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer

  • VS-7375Phase 24 trials

    Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)

  • BT5528nuzefatide pevedotinPhase 23 trials

    BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer

  • RNK08954Phase 23 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor Cancer, PDAC, KRAS G12D Mutations

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.